Deep eutectic ionic liquids for therapeutics
Transforming ionic liquids into healthcare solutions
Deep eutectic ionic liquids for therapeutics
Transforming ionic liquids into healthcare solutions
Who We Are
Our Advantage
Our Mission
CAGE Bio Inc., currently a resident company at Johnson & Johnson Innovation, JLABS @ MBC BioLabs, is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology.
Our Mission
Our Advantage
Our Mission
We believe that systemic exposure to drugs should be an exception. Our mission is to develop highly
effective products for localized treatment thereby minimizing side effects from systemic exposure.
Our Advantage
Our Advantage
Our Advantage
Deep eutectic ionic liquids exhibit broad-spectrum antimicrobial action in addition to exceptional solvation and permeation enhancement. Deep eutectic ionic liquids have shown the ability to deliver proteins (eg insulin) and charged macromolecules (eg siRNA) across the stratum corneum.
LEADERSHIP
Nitin Joshi, CEO
Carmine J. Durham, CSO
Carmine J. Durham, CSO
20+ years in drug development through approvals in the US and EU. Held senior positions at Elan, Alkermes, ALZA (J&J). Co-Founder, Incline Therapeutics acquired by The Medicines Company.
Carmine J. Durham, CSO
Carmine J. Durham, CSO
Carmine J. Durham, CSO
30+ years experience in pharma and med tech operations. Held senior positions at Knoll/BASF Pharma, Abbott Laboratories, and BoneCare Int’l. (acquired by Genzyme). Co-Founder and former CEO of Zurex Pharma.
Srini Sripada, CCO
Carmine J. Durham, CSO
Srini Sripada, CCO
20+ years’ experience building iconic brands including Campbell Soup, Advil analgesics, & Vaseline skin care at blue-chip marketing organizations (P&G, Unilever, Campbell Soup, Pfizer).
Welcome! Check out our latest news.
CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea.
Now Enrolling!